Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCQ908 in familial chylomicronemia syndrome
NL-OMON39328Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pradigastat in primary chylomicronemia (FCS) (3 arms), sponsored by Novartis. Primary endpoint: Percent change in fasting triglycerides from baseline to 12 weeks. Started Oct 2012; status: active, not recruiting.
02
Drugs
pradigastat
03
Conditions
primary chylomicronemia (FCS)
Beyond the preview
Go deeper on NL-OMON39328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39328.